Evonik, one of the world leaders in specialty chemicals, has entered into a long-term supply agreement with Phathom Pharmaceuticals, a US biopharmaceutical company focused on developing and commercializing new treatments for gastric acid-related diseases. Through the agreement Evonik will produce large-scale volumes of vonoprazan at its FDA-inspected manufacturing sites in Tippecanoe, Indiana, USA and Dossenheim, Germany.
